Travere Therapeutics, Inc. TVTX FILSPARI — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s filspari — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s FILSPARI — total revenue?
- Travere Therapeutics, Inc. (TVTX) reported FILSPARI — total revenue of $105.15M in Q1 2026.
- How has Travere Therapeutics, Inc.'s FILSPARI — total revenue changed year-over-year?
- Travere Therapeutics, Inc.'s FILSPARI — total revenue increased by 88.2% year-over-year, from $55.88M to $105.15M.
- What does FILSPARI — total revenue mean?
- Represents the total gross revenue generated from the sale of the specific pharmaceutical product or therapeutic asset. This metric reflects the market adoption and commercial performance of the therapy within its target patient population. It is a primary indicator of the product's growth trajectory and its contribution to the company's overall top-line performance.